Next Investors logo grey

MyFiziq June quarter ends on a high with receipt of US$450,000


Published 30-JUN-2020 09:41 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

MyFiziq Limited (ASX:MYQ) has received the tranche 2 payment of US$450,000 under the convertible note subscription deed announced with Asia Cornerstone Asset Management.

As announced on June 1, 2020, under the terms of the Convertible Note Subscription Deed with ACAM, MYQ was entitled to receive a total of US$1.5 million in 4 tranches, at this payment of US$450,000 represents the tranche two disbursement.

Management said that it was pleased with the progress made this quarter on several fronts.

The company highlighted these sentiments in an extremely positive update on the group’s operational performance in the last three months, highlighting MyFiziq’s highly promising outlook as it enters fiscal 2021.

As featured in finfeed yesterday, there have been numerous strategic developments on many fronts with important collaborative deals struck which will see broader applications of the company’s technologies, together with marketing arrangements which should see the group’s body measurement technology embraced by millions of people.

In brief, these operational and financial milestones can be summarised as follows.

07 - MYQ - dot points.PNG

Targeting multiple markets

Importantly, potential users of the technologies come from a wide range of sectors and demographics as it has applications for government and corporate organisations, as well as uses in the medical field, right through to personal monitoring, particularly in the health and fitness arena.

MyFiziq has developed this capability by leveraging the power of computer vision, machine learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry.

Body measurements provide more important information about health, risk and physical change than simply measuring weight.

MyFiziq simplifies the collection of these measurements, conveniently and cost-effectively, whilst removing the margin of human error present in traditional methods.

Investors have understood the significant upside potential as the company enters fiscal 2021 with its shares having soared from approximately 7 cents towards the end of March to close at 30 cents on June 9, a level that they are again pushing up towards despite volatility in broader equity markets.

The following chart demonstrates the significant outperformance over the last three months against the S&P/ASX All Ordinaries index (XAO - green line).

07 - MYQ - price chart.PNG

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.